MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Karyopharm Therapeutics Inc. (NASDAQ: KPTI)*
Organization & Developments: Karyopharm
Parents
Karyopharm Therapeutics Inc. (NASDAQ: KPTI)*
Children
*Biotech focused on nuclear transport technology for applications in the treatment of cancer, autoimmune disease, and HIV
*Commercial-stage oncology company best known for XPOVIO (selinexor), with late-stage expansion programs intended to broaden its franchise beyond current multiple myeloma and DLBCL revenues.
2014: Karyopharm gets first of what it hopes to be several orphan designations
2019: Biotech Analysis Central Preview Series: Karyopharm Therapeutics_seekingalpha.com
2019: FDA Staff Hammers Karyopharm Cancer Drug on Safety, Efficacy Concerns
2019: Karyopharm bags an upset win at the FDA as regulators OK myeloma drug despite a host of objections – Endpoints News
2019: Karyopharm Gets Accelerated FDA Approval for Myeloma Drug
2019: Revisiting Karyopharm Therapeutics_seekingalpha.com
2020: Karyopharm Is Extremely Cheap After Recent Sell-Off
2020: Karyopharm Therapeutics: Current Share Price Under-Reflects The Inherent Value
2020: Karyopharm Therapeutics: XPOVIO Sales Progress & Upcoming Milestones_seekingalpha.com
2020: The company received approval for Selinexor in July of this year for the treatment of Quadruple Refractory Multiple Myeloma. Selinexor's brand name is XPOVIO.
2021: Karyopharm Stock: Rationale For Bullishness
2021: Karyopharm: Strong Potential, Low Price, Looks Investible
2021: Revisiting Karyopharm Therapeutics
2022: Karyopharm Therapeutics Inc. 2022 Q3 - Results - Earnings Call Presentation_seekingalpha.com
2022: Karyopharm: Market Is Overlooking Growth_seekingalpha.com
2022: Karyopharm: Recent Sell-Off Hits A New Buy Target_ seekingalpha.com
2024: Karyopharm Therapeutics Inc. 2023 Q4 - Results - Earnings Call Presentation
2024: Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)
2025: Karyopharm lays off more workers as hunt for strategic alternatives turns up short
Organization & Developments: Karyopharm (Archives 2014-2018)
Jumps
*Key People: Karyopharm
Finance & Acquisitions: Karyopharm